Excreted Unchanged %
None
Half-Life (Normalesrd) Hours
7.6/Unchanged
Plasma Protein Binding %
97-99
Volume Of Distribution L/Kg
No data
Dose For Normal Renal Function
600 mg bid
Adjustment For Renal Failure Method
D
Adjustment For Renal Failure Gfr, Ml/Min >50 [Recommended Level]
100% [B]
Adjustment For Renal Failure Gfr, Ml/Min 10-50 [Recommended Level]
75% [B]
Adjustment For Renal Failure Gfr, Ml/Min <10 [Recommended Level]
50% [B]
Supplement For Dialysis [Recommendation Level]: Ihd
IHD: None, [D]
Supplement For Dialysis [Recommendation Level]: Pd
PD: Dose for GFR <10, [D]
Supplement For Dialysis [Recommendation Level]: Crrt
CRRT: Not applicable
References
Manninen V, Malkonen M, Eisalo A. Gemfibrozil treatment of dyslipidaemias in renal failure with uremia or in the nephrotic syndrome. Res Clin Forums. 1982; 4: 113-8. [PMID unavailable] / Todd PA, Ward A. Gemfibrozil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in dyslipidaemia. Drugs. 1988; 36: 314-39. [PMID: 3056692]
Toxicity Notes
Rhabdomyolysis with high doses of statin drugs. Caution if used with rosuvastatin.